Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1993 Dec;110(4):1483–1490. doi: 10.1111/j.1476-5381.1993.tb13989.x

Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide.

R G Pertwee 1, L A Stevenson 1, G Griffin 1
PMCID: PMC2175863  PMID: 8306090

Abstract

1. Mice pretreated intraperitoneally for 2 days with delta-9-tetrahydrocannabinol (delta-9-THC) at a dose of 20 mg kg-1 day-1 and then challenged intravenously with this drug, 24 h after the second pretreatment, showed a 6 fold tolerance to the hypothermic effect of delta-9-THC. This pretreatment also induced tolerance to the hypothermic effects of the cannabimimetic agents, CP 55,940 (4.6 fold) and WIN 55,212-2 (4.9 fold), but not to the hypothermic effect of the putative endogenous cannabinoid, anandamide. 2. Vasa deferentia removed from mice pretreated intraperitoneally with delta-9-THC twice at a dose of 20 mg kg-1 day-1 were less sensitive to its inhibitory effect on electrically-evoked contractions than vasa deferentia obtained from control animals. The cannabinoid pretreatment induced a 30 fold parallel rightward shift in the lower part of the concentration-response curve of delta-9-THC and a marked reduction in the maximal inhibitory effect of the drug. It also induced tolerance to the inhibitory effects on the twitch response of CP 55,940 (8.7 fold), WIN 55,212-2 (9.6 fold) and anandamide (12.3 fold). 3. The results confirm that cannabinoid tolerance can be rapid in onset and support the hypothesis that it is mainly pharmacodynamic in nature. The finding that in vivo pretreatment with delta-9-THC can produce tolerance not only to its own inhibitory effect on the vas deferens but also to that of three other cannabimimetic agents, suggests that this tissue would be suitable as an experimental model for investigating the mechanisms responsible for cannabinoid tolerance.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
1483

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Compton D. R., Prescott W. R., Jr, Martin B. R., Siegel C., Gordon P. M., Razdan R. K. Synthesis and pharmacological evaluation of ether and related analogues of delta 8-, delta 9-, and delta 9,11-tetrahydrocannabinol. J Med Chem. 1991 Nov;34(11):3310–3316. doi: 10.1021/jm00115a023. [DOI] [PubMed] [Google Scholar]
  2. Devane W. A., Hanus L., Breuer A., Pertwee R. G., Stevenson L. A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992 Dec 18;258(5090):1946–1949. doi: 10.1126/science.1470919. [DOI] [PubMed] [Google Scholar]
  3. Fitton A. G., Pertwee R. G. Changes in body temperature and oxygen consumption rate of conscious mice produced by intrahypothalamic and intracerebroventricular injections of delta 9-tetrahydrocannabinol. Br J Pharmacol. 1982 Feb;75(2):409–414. doi: 10.1111/j.1476-5381.1982.tb08802.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fride E., Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol. 1993 Feb 9;231(2):313–314. doi: 10.1016/0014-2999(93)90468-w. [DOI] [PubMed] [Google Scholar]
  5. Gray G. A., Hedley D., Pertwee R. G. Enhancement of the hypothermic response of mice to delta-9-tetrahydrocannabinol by subhypothermic doses of chlorpromazine and phentolamine. Neuropharmacology. 1987 Feb-Mar;26(2-3):229–235. doi: 10.1016/0028-3908(87)90213-9. [DOI] [PubMed] [Google Scholar]
  6. Jansen E. M., Haycock D. A., Ward S. J., Seybold V. S. Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. Brain Res. 1992 Mar 13;575(1):93–102. doi: 10.1016/0006-8993(92)90428-c. [DOI] [PubMed] [Google Scholar]
  7. Little P. J., Compton D. R., Johnson M. R., Melvin L. S., Martin B. R. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther. 1988 Dec;247(3):1046–1051. [PubMed] [Google Scholar]
  8. Martin B. R., Compton D. R., Thomas B. F., Prescott W. R., Little P. J., Razdan R. K., Johnson M. R., Melvin L. S., Mechoulam R., Ward S. J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav. 1991 Nov;40(3):471–478. doi: 10.1016/0091-3057(91)90349-7. [DOI] [PubMed] [Google Scholar]
  9. Pacheco M., Childers S. R., Arnold R., Casiano F., Ward S. J. Aminoalkylindoles: actions on specific G-protein-linked receptors. J Pharmacol Exp Ther. 1991 Apr;257(1):170–183. [PubMed] [Google Scholar]
  10. Pertwee R. G., Stevenson L. A., Elrick D. B., Mechoulam R., Corbett A. D. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol. 1992 Apr;105(4):980–984. doi: 10.1111/j.1476-5381.1992.tb09088.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Pertwee R. G., Tavendale R. Effects of delta9-tetrahydrocannabinol on the rates of oxygen consumption of mice. Br J Pharmacol. 1977 Aug;60(4):559–568. doi: 10.1111/j.1476-5381.1977.tb07535.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pertwee R. The evidence for the existence of cannabinoid receptors. Gen Pharmacol. 1993 Jul;24(4):811–824. doi: 10.1016/0306-3623(93)90154-p. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES